Market closed
United Therapeutics/$UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Ticker
$UTHR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,305
Website
UTHR Metrics
BasicAdvanced
$13B
11.54
$24.64
0.64
-
Price and volume
Market cap
$13B
Beta
0.64
52-week high
$403.35
52-week low
$230.39
Average daily volume
517K
Financial strength
Current ratio
5.248
Quick ratio
4.805
Long term debt to equity
0.504
Total debt to equity
5.255
Interest coverage (TTM)
33.71%
Management effectiveness
Return on assets (TTM)
12.44%
Return on equity (TTM)
19.23%
Valuation
Price to earnings (TTM)
11.539
Price to revenue (TTM)
4.466
Price to book
1.98
Price to tangible book (TTM)
2.01
Price to free cash flow (TTM)
11.892
Growth
Revenue change (TTM)
23.63%
Earnings per share change (TTM)
24.38%
3-year revenue growth (CAGR)
19.52%
3-year earnings per share growth (CAGR)
34.80%
What the Analysts think about UTHR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
UTHR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
UTHR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
UTHR News
AllArticlesVideos
United Therapeutics: Don't Fear The Patent Expiration Too Much
Seeking Alpha·3 weeks ago
United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $13B as of April 16, 2025.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 11.54 as of April 16, 2025.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.